Today: 9 June 2026
Browse Category

TSX:EDV 9 October 2025 - 28 January 2026

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 fell 0.3% to 10,177.85 as a stronger pound hit overseas earners. Gold reached a record above $5,300 an ounce, boosting miners, while Marston’s dropped up to 16% on flat 17-week sales. Traders awaited the U.S. Fed’s policy decision later Wednesday. Oil prices eased but held near four-month highs after U.S. supply disruptions.
28 January 2026
········
FTSE 100 slips as Barclays takes a hit from Trump’s credit-card cap push; gold miners climb

FTSE 100 slips as Barclays takes a hit from Trump’s credit-card cap push; gold miners climb

Barclays dropped 4% after U.S. President Trump called for a 10% cap on credit-card interest rates, weighing on UK stocks. The FTSE 100 slipped 0.1% by 0823 GMT, while sterling rose 0.3% to about $1.34. Miners gained as gold hit a record $4,563.61 an ounce. HSBC and other European banks also fell on concerns over U.S. policy risks.
12 January 2026
······
FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

The FTSE 100 closed at a record high near 9,548 in early October, up 15–17% year-to-date, led by surges in banks, miners, and healthcare stocks. Gains followed strong earnings, regulatory relief, and gold topping $4,000/oz. A weak pound boosted international firms’ profits. Political shifts and a new UK-India trade deal also moved markets, while Middle East tensions kept oil and gold prices elevated.
9 October 2025
······

Stock Market Today

  • U.S. Inflation Poised to Exceed 4% for First Time Since 2023, Pressures Mount on Fed
    June 9, 2026, 10:06 AM EDT. U.S. inflation is set to surpass 4% for the first time since 2023, signaling rising consumer prices and intensifying economic pressures. This uptick, measured by the year-over-year increase in the Consumer Price Index (CPI), highlights renewed challenges for the Federal Reserve (Fed) as it grapples with balancing inflation control against economic growth. The rise in inflation may influence the Fed's monetary policy decisions amid concerns over sustained price increases impacting households and businesses for the remainder of the year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop